专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2009125987A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶钙通道阻断剂的缓释隔室和具有血管紧张素-2受体阻断剂的速释隔室的药物制剂。本发明提供了这样的药物制剂，其中二氢吡啶钙通道阻断剂和血管紧张素-2受体阻断剂分别包含在每个隔室中并且其释放受到控制。由于制剂的每个不同区室中所含的每种不同药物在不同时间释放，本发明的药物制剂使药物之间的拮抗作用和副作用最小化，并使药物的特定作用最大化。通过本发明的两种药物之间的特定组合的药物制剂与单独施用每种药物或简单联合施用药物相比，在治疗或预防疾病方面具有显着的良好效果。

22. 发明申请

WO2009127974A3 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127974A3
公开(公告)日：2010-03-25
申请号：PCT/IB2009006277
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/40 , A61K31/44 , A61K47/38 , A61P9/00 , A61P13/12
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation comprising: an early release portion comprising as a pharmaceutical active ingredient a statin-based hypolipidic agent, an isomer thereof, or a pharmaceutically acceptable salt thereof; and a slow release portion comprising as a pharmaceutical active ingredient a dihydropyridine-based calcium channel blocking agent, an isomer thereof, or a pharmaceutically acceptable salt thereof. When compared with a single formulation of each of the drugs or a simple combination formulation of the drugs, the pharmaceutical formulation according to the present invention comprising an early release portion comprising a statin-based hypolipidic agent and a slow release portion comprising a dihydropyridine-based calcium channel blocking agent is pharmaceutically, scientifically, and economically very useful in preventing or treating cardiovascular disease, pulmonary heart disease, pulmonary disease, or kidney disease of patients who have a metabolic syndrome, insulin resistance, diabetes, or prediabetes. The formulation of the present invention is effective in preventing antagonistic and side effects between the drugs by making the dissolution rate of the statin-based hypolipidic agent different from that of the dihydropyridine-based calcium channel blocking agent, and in facilitating patient compliance in taking the drugs by administering the two different drugs simultaneously.
摘要翻译：本发明提供一种药物制剂，其包含：早期释放部分，其包含作为药物活性成分的基于他汀类的降血糖剂，其异构体或其药学上可接受的盐; 以及缓释部分，其包含基于二氢吡啶的钙通道阻断剂，其异构体或其药学上可接受的盐作为药物活性成分。当与药物的单一制剂或药物的简单组合制剂相比时，根据本发明的药物制剂包含早期释放部分，其包含基于他汀类的降血脂药和包含基于二氢吡啶的缓释部分钙通道阻断剂在预防或治疗具有代谢综合征，胰岛素抵抗，糖尿病或糖尿病前期的患者的心血管疾病，肺心病，肺部疾病或肾脏疾病方面在药学，科学和经济上非常有用。本发明的制剂通过使基于他汀类的降血糖剂与二氢吡啶类钙通道阻断剂的溶解速率不同而使药物的拮抗作用和副作用有效，并且为了便于患者服用药物同时服用两种不同药物。

23. 发明申请

WO2009104939A3 PHARMACEUTICAL PREPARATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009104939A3
公开(公告)日：2009-11-19
申请号：PCT/KR2009000856
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SON JAW WOON , KIM JIN WOOK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SON JAW WOON , KIM JIN WOOK
IPC分类号： A61K9/52 , A61K9/00 , A61K9/22 , A61K31/165 , A61K31/41 , A61K47/00
CPC分类号： A61K9/209 , A61K9/0004 , A61K31/165 , A61K31/41
摘要： Disclosed is a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active component, and a compartment containing HMG-CoA reductase inhibitor as a pharmacologically active component, wherein one of compartments is an advance release compartment and the other of the compartments is a retard release compartment. The combination preparation of the present invention delivers the renin inhibitor and HMG-CoA reductase inhibitor with a time difference at a specific speed, reducing undesirable side-effects, improving the potentiating effect and allowing for ease in teaching dosing regimens and enhanced patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndrome, cardiovascular disease, renal disease and the like as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.
摘要翻译：公开了一种药物制剂，其包含含有作为药理活性成分的肾素抑制剂的隔室和含有HMG-CoA还原酶抑制剂作为药理活性成分的隔室，其中一个隔室是提前释放隔室而另一个隔室是缓释隔室。本发明的组合制剂以特定的速度递送肾素抑制剂和HMG-CoA还原酶抑制剂，具有时间差异，减少不希望的副作用，改善增强作用，并且容易教示给药方案和增强患者依从性。此外，本发明的药物制剂与单独服用药物成分的复合药物疗法相比在预防或治疗代谢综合征，心血管疾病，肾病等方面具有药理学，临床，科学和经济优势同时。

24. 发明申请

WO2012087017A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1多肽或其片段及其制备方法
公开(公告)号：WO2012087017A3
公开(公告)日：2012-08-16
申请号：PCT/KR2011009914
申请日：2011-12-21
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/715 , A61K38/17 , A61P35/00 , C12N15/12
CPC分类号： C07K14/7151 , A61K38/00 , C07K14/70575
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof which is bound to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibits improved binding force to the tumor necrosis factor and improved protease resistance.
摘要翻译：本发明涉及在体内或离体结合肿瘤坏死因子的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出对肿瘤坏死因子的改进的结合力和改善的蛋白酶抗性。

25. 发明申请

WO2011049350A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1多肽或其片段及其制备方法
公开(公告)号：WO2011049350A3
公开(公告)日：2011-10-13
申请号：PCT/KR2010007160
申请日：2010-10-19
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , C12N15/28 , C12N15/63
CPC分类号： C07K14/70578
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
摘要翻译：本发明涉及体内或离体与肿瘤坏死因子偶联的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出对体内蛋白酶活性的改善的抗性，并因此表现出改善的生物利用度和改善的吸收率。

26. 发明申请

WO2010085086A3 MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND MANUFACTURING METHOD THEREOF 审中-公开
标题翻译：改性人类血小板聚糖片段及其制造方法
公开(公告)号：WO2010085086A3
公开(公告)日：2010-12-09
申请号：PCT/KR2010000368
申请日：2010-01-20
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , JEONG JAE KAP , LEE SUNG YUL , SONG YEON JUNG , SHIM WON JO
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , JEONG JAE KAP , LEE SUNG YUL , SONG YEON JUNG , SHIM WON JO
IPC分类号： C07K14/505 , A61K38/17 , C12N15/12 , C12N15/63
CPC分类号： C07K14/515 , A61K38/196
摘要： The present invention provides a modified human thrombopoietin polypeptide fragment that has platelet proliferative activity in vivo and in vitro and enhanced resistance to protease existing in vivo.
摘要翻译：本发明提供了在体内和体外具有血小板增殖活性的改良人类血小板生成素多肽片段，并增强了体内存在蛋白酶的抗性。

27. 发明申请

WO2012036410A3 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
公开(公告)号：WO2012036410A3
公开(公告)日：2012-05-31
申请号：PCT/KR2011006621
申请日：2011-09-07
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , A61K38/19 , C07K14/525 , C12N15/63
CPC分类号： C07K14/7151 , A61K38/00 , A61K38/19 , C07K14/525 , C07K14/705 , C12N15/63
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to bind to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. According to the present invention, the modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof exhibits improved binding force to the tumor necrosis factor.

28. 发明申请

WO2011049400A3 PHARMACEUTICAL COMPOSITION CONTAINING ACID ADDITION SALT OF N,N-DIMETHYL IMIDOCARBONIMIDIC DIAMIDE FOR ANTI-CANCER 审中-公开
标题翻译：含有N，N-二甲基咪唑并二恶烷的抗酸剂的酸加成盐的药物组合物
公开(公告)号：WO2011049400A3
公开(公告)日：2011-11-03
申请号：PCT/KR2010007273
申请日：2010-10-22
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , KIM YOUNG WOONG , OH BYUNG KYU , LEE SEUNG HO
发明人： KIM SUNG WUK , JUN SUNG SOO , KIM YOUNG WOONG , OH BYUNG KYU , LEE SEUNG HO
IPC分类号： A61K31/155 , A61P3/04 , A61P3/06 , A61P3/10
CPC分类号： A61K31/155 , A61K45/06 , A61K2300/00
摘要： Provided is a use for anticancer of dichloroacetic acid salt or aminooxyacetic acid salt of N,N-dimethyl imidodicarbonimidic diamide (metformin). According to the present invention, the acid addition salt of metformin synergistically causes anticancer effect by AMPK enzyme activation of metformin and anticancer effect of organic acids used as a salt, and thus shows a remarkable anticancer effect. In addition, the acid addition salt has superior physiochemical properties such as solubility, stability, non-hygroscopicity, processibility as a tablet formulation and the like, and has lower toxicity compared with metformin hydrochloride. Therefore, the acid addition salt can be useful as a pharmaceutically acceptable salt.
摘要翻译：提供了N，N-二甲基亚氨基二甲酰亚胺二酰胺（二甲双胍）的二氯乙酸盐或氨基氧乙酸盐的抗癌剂的用途。根据本发明，二甲双胍的酸加成盐协同地引起二甲双胍的AMPK酶活化和作为盐的有机酸的抗癌作用的抗癌作用，因此显示出显着的抗癌作用。此外，酸加成盐具有优异的物理化学性质如溶解性，稳定性，非吸湿性，作为片剂制剂的加工性等，并且与二甲双胍盐酸盐相比具有较低的毒性。因此，酸加成盐可用作药学上可接受的盐。

29. 发明申请

WO2011049350A2 MODIFIED HUMAN TUMOR NECROSIS FACTOR RECEPTOR-1 POLYPEPTIDE OR FRAGMENT THEREOF, AND METHOD FOR PREPARING SAME 审中-公开
标题翻译：修饰的人肿瘤坏死因子受体-1聚糖或其片段及其制备方法
公开(公告)号：WO2011049350A2
公开(公告)日：2011-04-28
申请号：PCT/KR2010007160
申请日：2010-10-19
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , PARK SEUNG KOOK , KIM SONG YOUNG , KIM EUN SUN , JEONG JAE KAP , KIM HA NA , SONG YEON JUNG
IPC分类号： C07K14/705 , C12N15/28 , C12N15/63
CPC分类号： C07K14/70578
摘要： The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.
摘要翻译：本发明涉及在体内或体外与肿瘤坏死因子偶联的修饰的人肿瘤坏死因子受体-1多肽或其片段。根据本发明的修饰的人肿瘤坏死因子受体-1多肽或其片段表现出改善的抗体内蛋白酶活性，因此表现出改进的生物利用度和改善的吸收速率。

30. 发明申请

WO2010077061A3 PHARMACEUTICAL FORMULATIONS CONTAINING ANTIVIRAL DRUGS 审中-公开
标题翻译：含有抗病毒药物的药物制剂
公开(公告)号：WO2010077061A3
公开(公告)日：2010-11-04
申请号：PCT/KR2009007880
申请日：2009-12-29
申请人： HANALL BIOPHARMA CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM
IPC分类号： A61K31/70 , A61K9/22 , A61K31/513 , A61K47/30 , A61K47/38 , A61K47/42 , A61P31/12
CPC分类号： A61K31/513 , A61K31/70 , A61K47/38 , A61K47/42
摘要： The present invention relates to pharmaceutical formulations containing antiviral drugs and sustained-release materials, and to pharmaceutical formulations having an immediate release compartment containing drugs associated with cytochrome P450, as well as an extended release compartment containing antiviral drugs and sustained-release materials. The formulations of the present invention reduce interactions between antiviral drugs to increase the effects of the drugs and to decrease side effects.
摘要翻译：本发明涉及含有抗病毒药物和缓释材料的药物制剂，以及具有含细胞色素P450相关药物的速释隔室的药物制剂，以及含有抗病毒药物和缓释材料的缓释隔室。本发明的制剂减少抗病毒药物之间的相互作用以增加药物的作用并减少副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式